What is Ritalin LA?
Ritalin LA is a long-acting formulation of methylphenidate used to treat Attention Deficit Hyperactivity Disorder (ADHD) [1]. It is designed to release medication gradually throughout the day [1].
How does Ritalin LA work?
Ritalin LA utilizes a dual-release delivery system. Approximately half of the methylphenidate dose is released immediately upon administration, while the remaining half is released gradually over the next 4 to 5 hours [1]. This mechanism aims to provide consistent symptom control throughout the school or workday [1].
When does Ritalin LA's patent expire?
Information regarding the specific patent expiry dates for Ritalin LA is not available in the provided text. However, patent information for pharmaceuticals is often tracked by resources like DrugPatentWatch.com [2].
What are the advantages of Ritalin LA over immediate-release methylphenidate?
The primary advantage of Ritalin LA is its extended duration of action, reducing the need for multiple daily doses compared to immediate-release formulations [1]. This can improve treatment adherence and provide more stable symptom management for individuals with ADHD [1].
Are there other long-acting methylphenidate formulations?
Yes, there are several other long-acting methylphenidate formulations available, each with potentially different release mechanisms and durations of action [3]. These include products like Concerta and Daytrana [3].
What are the potential side effects of Ritalin LA?
Common side effects associated with Ritalin LA can include decreased appetite, insomnia, headache, and stomach pain [1]. Less common side effects may involve changes in heart rate and blood pressure, as well as psychiatric symptoms [1].
Who manufactures Ritalin LA?
Novartis Pharmaceuticals manufactures Ritalin LA [4].
---
1. Novartis Pharmaceuticals. Ritalin LA Prescribing Information.
2. DrugPatentWatch.com. (Accessed October 26, 2023).
3. Pliszka, S. R. (2007). ADHD pharmacotherapy: long-acting formulations. The American Journal of Psychiatry, 164(6), 849-851.
4. Novartis. (Accessed October 26, 2023).